-
FDA Drug Approvals Q1 2024
24 Apr 2024 15:11 GMT
… Phase 3 RATIONALE 302 trial. Median overall survival ( … – Accelerated approval for treatment of adults with relapsed or … chronic immune thrombocytopenia (ITP) who experienced insufficient … indicated for adults to treat thrombocytopenia associated with chronic …
-
Sanofi’s Rilzabrutinib Meets Primary Endpoint in ITP
23 Apr 2024 21:25 GMT
… chronic immune thrombocytopenia (ITP). The safety … ITP.
Rilzabrutinib was granted Fast Track Designation by the U.S. FDA … for the treatment of ITP in November … 2020 and was previously granted Orphan Drug Designation.
ITP …
-
BDNF Levels Links to Long-term Success in Intensive PTSD Treatment Among Veterans
27 Mar 2024 15:00 GMT
The following is a summary of “Brain derived neurotrophic factor and treatment outcomes among veterans attending an intensive treatment program for posttraumatic stress disorder,” published in the February 2024 issue of Psychiatry by Zalta et al.
PTSD …
-
Immune Thrombocytopenia Market Report 2032: Epidemiology, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight
27 Mar 2024 12:56 GMT
… Drug Administration (FDA) granted approval for avatrombopag (DOPTELET; Dova Pharmaceuticals) for treating … Furthermore, corticosteroid medications, offering … drugs is anticipated to challenge market growth. Moreover, declining rates of pediatric ITP treatment …
-
Sobi shares positive phase 3 results for Doptelet in paediatric patients with rare blood disorder ITP
27 Mar 2024 12:52 GMT
… Abad-Franch, head of research, development and medical affairs, and chief … [Doptelet] treatment would be beneficial for patients living with ITP.”
Beyond ITP, Doptelet … holds approvals to treat thrombocytopenia in …
-
FDA Grants ODD to Cevidoplenib for the Treatment of Immune Thrombocytopenia
25 Mar 2024 19:15 GMT
About the Trial
Trial Name: Study … drug designation (ODD) for the treatment of patients with immune thrombocytopenia (ITP … inhibitor that treats patients with ITP, and currently treats rheumatoid … important milestone in the development of cevidoplenib and …
-
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
22 Mar 2024 00:00 GMT
… trial may be used to support a future New Drug … the treatment of patients with wAIHA and the further development of … any prescription drugs including the ones under development. CONTACTS
Investor … complex‐mediated inflammation. J Pharmacol Exp Ther. 2006; 319 …
-
FDA Grants Orphan Drug Designation to Cevidoplenib for ITP
21 Mar 2024 14:55 GMT
… and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immune thrombocytopenia (ITP … (bleeding in the brain). ITP treatment consists of the administration of … generation EGFR inhibitor being developed by Janssen Pharma and Yuhan Corp. for …
-
Takeda reports interim findings from immune thrombocytopenia trial
14 Mar 2024 12:58 GMT
… orphan drug and fast track designations for mezagitamab for the treatment of ITP … effects or relapse despite treatment.”
The latest development comes after the company … from Phase IIb trial of TAK-861 for treating patients with narcolepsy …
-
Takeda: Mezagitamab Phase 2 Trial Shows Positive Results In Primary Immune Thrombocytopenia
13 Mar 2024 14:42 GMT
Takeda Pharmaceutical Co. Ltd. (TAK,TKPHF. … caused, partly, by the development of autoantibodies to platelets, which … in their depletion.
The trial evaluated three different doses of … received Orphan Drug Designation for the treatment of ITP from the …